News Articles

FIND Collaborates with SpeeDx and QuantuMDx SYDNEY -Thursday 7 November 2019  

(BUSINESS WIRE)-- SpeeDx Pty. Ltd. and QuantuMDx Group Ltd. today announced a collaboration with the Foundation for Innovative New Diagnostics (FIND). The global non-profit organization drives development and delivery of diagnostics to combat major diseases affecting the world’s poorest...

SpeeDx Pty. Ltd. Raises $15 Million From U.S. Investment Partnership -Tuesday 6 August 2019  

(BUSINESS WIRE) -- SpeeDx Pty. Ltd., the developer of transformative new molecular diagnostic solutions, today announced it had raised up to US $10 million in additional equity investment from US-based Northpond Ventures. This follows an original investment of US $5 million from Northpond...

SpeeDx Receives Clearance from Health Canada for ResistancePlus® MG Test -Tuesday 16 July 2019  

(BUSINESS WIRE)-- SpeeDx Pty. Ltd. today announced ResistancePlus® MG has been cleared by Health Canada and is now available for sale across all Canadian provinces (not currently available in the U.S.). The molecular diagnostic test detects the sexually transmitted infection (STI) Mycoplasma...

SpeeDx announce a collaborative agreement with GSK to supply tests and technology -Tuesday 25 June 2019  

(BUSINESS WIRE)-- SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, has signed a collaborative agreement with GSK, to provide a combination of existing tests and custom test development to support certain GSK antibiotic clinical trials and new product...

SpeeDx Receives Clearance for PlexPCR Respiratory Virus Test -Tuesday 14 May 2019  

(BUSINESS WIRE) -- SpeeDx Pty. Ltd. today announced the clearance of the PlexPCR® RespiVirus* test from the Australian Therapeutic Goods Administration (TGA). The test utilises market-leading PlexPCR® technology to detect 11 viral respiratory-illness causing pathogens and allows laboratories...

CORRECTING and REPLACING SpeeDx and Cepheid Announce Test Partnership -Wednesday 17 April 2019  

(BUSINESS WIRE) -- First sentence, seventh paragraph of release dated April 16, 2019 should read: “Currently, there is no FDA-cleared molecular diagnostic test for the combined detection of M. genitalium and macrolide resistance markers in the U.S. Cure rates for M.genitalium have been...

SpeeDx Distribution Network Expands to the Middle East -Tuesday 19 March 2019  

(BUSINESS WIRE)-- SpeeDx Pty. Ltd. have announced signing new partners Al Zahrawi Medical Supplies LLC for distribution of ResistancePlus® and PlexPCR® tests across UAE, Saudi Arabia, Oman, Bahrain, and Qatar. “Al Zahrawi Medical are the leading medical and diagnostic suppliers in the...

SpeeDx Develops Multiplex Test for Respiratory Viruses -Thursday 14 February 2019  

(BUSINESS WIRE)-- SpeeDx Pty. Ltd. today announced submission of their PlexPCR® RespiVirus test to the Therapeutic Goods Administration (TGA). The company anticipates clearance in time for the Australian 2019 flu season. The test utilises SpeeDx market-leading PlexPCR® multiplex technology,...